tbuckley/cabot-search huggingface dataset:
Phase I/pharmacology study of intraperitoneal (IP) 3–5 day topotecan alone and with cisplatin:on day 1: potential for consolidation in ovarian cancer
Authors: E. Andreopoulou, T. Chen, L. Liebes, J. Lu, S. Moore, E. Fusco, P. Liu, J. Curtin, H. Hochster, F. Muggia
Journal: Journal of Clinical Oncology (2005)

5045 Background: Consolidation following 1st-line treatment is a strategy being explored to improve results in advanced ovarian cancer. Topotecan has schedule dependent toxicity alone and combination with cisplatin. We sought to evaluate repetitive doses of IP topotecan alone and in combination with cisplatin. in patients with stage III ovarian cancers undergoing reassessment. Methods: Reasessed patients underwent placement of IP catheters and enrolled in a dose-escalation design to the following levels: topotecan 1.5 mg D1–5 (level 0) alone and with cisplatin 50mg/m2 D1 and topotecan 1.5mg D1–3 (level I). Dose-limiting toxicity (DLT) led to de-escalation to topotecan 1.25mg D1–3 (level II), and topotecan 1.25 mg/m2 D1–5 (level III). Plasma and lactone topotecan was measured d1, d2 on cycles 1 and 2 with IP fluid total measured d2 on both cycles(a minimum of 4 cycles were planned). Results: 15 with epithelial ovarian or tubal cancer and 1 with gastric cancer were entered (number) at levels 0 (3), I (4), II (4), and III (5). Ovarian cancer patients had minimal (6) or no residuum (3) after platinum-based induction, 4 were entered for documented peritoneal recurrences, and 2 for cytologic recurrence after IP cisplatin/FUDR DLT (neutropenia) was noted in 7 patients at dose levels 1 and 3; grade 3 thrombocytopenia occurred in 2 at level 3. Other toxicities: grade 1hives (2) and creatinine elevations (2), S epidermidis and chemical peritonitis (1 each) after cycle 2. Patients treated at first reassessment had a recurrencence free survival not reached with > 42 w (62–148w) for all patients. Pharmacology demonstrates 20–100x pharmacologic advantage AUC IP/AUC plasma for topotecan. Conclusion: Topotecan has excellent local tolerance and myelosuppression is dose-limiting. IP consolidation with topotecan alone or with cisplatin at dose level II should be tested in Phase III trials. No significant financial relationships to disclose.
Abstract 323: Overexpression of Coupling Factor 6 Causes Salt-Induced Congestive Heart Failure by Tissue Acidosis-Mediated Reactive Oxygen Species
Authors: Toshihiro Ashitate
Journal: Circulation (2008)

Reactive oxygen species (ROS) is associated with the development of congestive heart failure (CHF) in animals and humans. We have showed that coupling factor (CF6), a component of ATP synthase, suppresses prostacyclin and nitric oxide generation by intracellular acidosis, which is closely related to the generation of ROS and CHF. On the other hand, high salt intake, one of the most important factors to initiate and exacerbate CHF, increases ROS generation. We thus investigated the role of CF6 in the genesis of CHF by using transgenic mice (TG) overexpressing CF6 and exposing them to high-salt diet. In TG, the introduced gene of human CF6 was expressed in overall tissues including the heart, and upregulated by 2 fold. Baseline echocardiographic data, ROS generation, protein expression of sarcoplasmic/endoplasmic reticulum of Ca 2+ -ATPase (SERCA)-2, associated with cardiac muscle relaxation, and phospholamban, and the gene expression related to ATP synthesis and glycolysis, and the genes α- and β-MHC in the heart were similar between 7-week-old TG and wild type mice (WT). When the mice were fed with high-salt diet (8% salt) for 20–24 weeks, fractional shortening of the left ventricle was decreased in TG compared to WT (29±3% vs 39±2%, p&lt; 0.05). The protein expression of SERCA-2 was decreased by 90±29% in TG compared with WT, whereas that of phospholamban, an inhibitor of SERCA-2, was increased by 141±31% in TG (both p&lt; 0.05). In cDNA microarray analysis of the heart, the genes related to ATP synthesis, such as ATP synthase (0.29±0.10 fold) and cytochrome C (0.30±0.04), and those related to glycolysis were decreased in TG mice (all p&lt; 0.05). The gene expression of β-MHC as the fetal isoform of MHC was increased in TG heart, whereas that of α-MHC as the adult isoform was unchanged. The myocardial level of 8-iso-prostaglandin F 2α , a marker of ROS generation, was increased by 83±31% in TG compared with WT (p&lt; 0.05). The mortality rate at the period of 35 weeks was greater in TG (7/14 (50%)) than in WT (1/13 (8%)) (p&lt; 0.05 by log rank test), although neither TG nor WT were dead under normal salt diet. These suggest that CF6 induces the development of mitochondrial dysfunction and systolic and diastolic dysfunction, and eventually causes CHF by enhancing of ROS generation.
Das Quecksilber; seine Gewinnung, technische Verwendung und Giftwirkung, mit eingehender Darstellung der gewerblichen Quecksilbervergiftung nebst Therapie und Prophylaxe.
Authors: Ernst W. Baader, Ernst Holstein
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue
CPR before medical services arrive more than doubles survival after cardiac arrest
Authors: S. Mayor
Journal: BMJ (2015)

Giving cardiopulmonary resuscitation before emergency medical services arrive more than doubles the 30 day survival rate in people who have a cardiac arrest out of hospital, shows a Swedish study reported in the New England Journal of Medicine .1

CPR is recommended by international guidelines as one of the most important early responses in people with a suspected cardiac arrest occurring out of hospital, in addition to calling for urgent medical help and defibrillation. But the value of bystander CPR has been debated because of a lack of clinical trial data to show that it is life saving.

Researchers analysed all …
Results of a phase I study of bendamustine in combination with ofatumumab, carboplatin, and etoposide (BOCE) for refractory or relapsed aggressive B-cell non-Hodgkin lymphomas (NHL).
Authors: Sameh Gaballa, Neil David Palmisiano, Aakanksha Asija, Andrew E. Chapman, Jennifer K. Cloud, Joanne E. Filicko-O'Hara, Lewis J. Rose, Michael J. Ramirez, Onder Alpdogan, Neal Flomenberg, Barbara Pro, Elena Gitelson, Mark Adam Weiss
Journal: Journal of Clinical Oncology (2014)

8556 Background: No salvage regimen has shown clear superiority in relapsed NHL. Bendamustine has single agent activity in relapsed aggressive NHL. We conducted a phase I trial using a novel RICE-like salvage regimen in which ofatumumab was substituted for rituximab and bendamustine replaced ifosfamide, combined with carboplatin and etoposide (BOCE) Methods: Patients (pts) with relapsed or refractory aggressive B NHL were eligible. The design was a standard 3+3 design using escalating doses of bendamustine [70, 90, and 120 mg/m2 D1-2] with ofatumumab (cycle 1: 300 mg D1, 1000 mg D3, cycle 2 and 3: 1000 mg D1), carboplatin AUC 5 D2 and etoposide 100mg/m2 D1-3. Results: Eleven pts were enrolled (7M/4F). Median age was 62 (range 53-75), 5 pts (45%) had diffuse large B NHL, 4 pts (36%) had grade 3 follicular NHL, 1 pt (9%) had mantle cell NHL, and 1 pt (9%) had transformed CLL. Five pts (46%) had refractory disease and 6 pts (56%) had relapsed disease. All pts with refractory disease were refractory to rituximab. All pts had stage III or IV disease. sAAIPI was: low-int 55%, high-int 36%, high risk 9%. ORR was 64% [CR: 5 pts (46%); PR: 2 pts (18%)]. Two pts (18%) had progressive disease and 1 pt (9%) had stable disease. Five pts (46%) subsequently underwent an allogeneic transplant. Four pts (36%) died, all of progressive disease. After a median follow-up of 6 months, the estimated 12-months OS is 63.5% DLT was not reached. Grade III-IV toxicity included neutropenia (82%), thrombocytopenia (64%), anemia (64%), lymphopenia (27%), febrile neutropenia (27%), hyponatremia (18%), and hypophosphatemia (18%). Six serious adverse events were reported in 4 pts including acute kidney injury, urinary tract infection, pleural effusion, GI bleeding, thromboembolic event and febrile Infusion related reactions occurred in 27% of pts (all grade I-II). Conclusions: The BOCE regimen is well tolerated in pts with relapsed or refractory aggressive NHL. A phase II trial with bendamustine at the dose of 120mg/m2 is ongoing. The advantage of this regimen over other commonly used salvage strategies is that it can be administered safely in the outpatient setting. Clinical trial information: NCT01458366.
Interleukin-4 Induces Homotypic Aggregation of Human Mast Cells by Promoting LFA-1/ICAM-1 Adhesion Molecules
Authors: Hano Toru, Tatsuo Kinashi, Chisei Ra, Shigeaki Nonoyama, Jun-ichi Yata, Tatsutoshi Nakahata
Journal: Blood (1997)
Effects of the pressure waweform during assisted mechanical ventilation on pulmonary stretch receptor and phrenic nerve activity in cats.
Authors: R Sindelar, H Ehrhardt, A Jonzon, E Rieger-Fackeldey, P Schaller, A Schulze, G Sedin
Journal: American Journal of Respiratory and Critical Care Medicine (2000)

Effects of the pressure waweform during assisted mechanical ventilation on pulmonary stretch receptor and phrenic nerve activity in cats.
Organic Reagents Used in Quantitative Inorganic Analysis
Authors: Wilhelm Prodinger, Stewart William Holmes, O. Baudisch
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Method of detection of local recurrence in patients following breast conserving surgery and its utility for surveillance
Authors: B. Taback, N. Hansen, K. Conway, A. Giuliano
Journal: Journal of Clinical Oncology (2006)

611 Background: It is estimated that approximately 10% of all breast cancer patients will develop local recurrence (LR) at 10 years. Routine surveillance for detection of early breast cancer recurrence is widely performed despite lack of conclusive evidence for an improvement in patient quality of life or potential for cure. A number of historical studies evaluating the effectiveness of routine screening for LR following treatment for early-stage breast cancer have suggested that the diagnosis of LR is more frequent during a routine visit and occurring in asymptomatic patients. However, differentiating the method of detection is not often elucidated. In this study we evaluated the manner in which patients presented with an isolated LR in clinical practice. Methods: Our routine patient follow-up consists of physical exam and mammogram every 6 mos for the first 2 years following breast conserving surgery (BCS) and yearly thereafter. We queried our prospectively collected breast cancer database (1632 patients from July 1986 - July 2004) for patients with an isolated LR following BCS (n=59 (3.6%); two patients had bilateral LRs). Medical records were not available for three patients. Results: At a median follow-up of 45 mos (range: 5–122 mos) there were 58 evaluable LRs: 15 DCIS, 31 infiltrating ductal carcinoma (IDC), 6 infiltrating lobular (ILC), 2 mixed IDC/ILC, 3 invasive cancers NOS and 1 unknown. Patient presentation was as follows: 25 were diagnosed by self-exam, 28 on screening mammogram, 2 were diagnosed by physician (includes one referral), and 3 unknown. Mammogram detected recurrences were more frequent among patients with DCIS whereas self-detected recurrences were more common in patients with IDC (79% vs 33% and 21% vs 67%, respectively; P&lt;0.2). Mean tumor size was larger in self-presentation (2.1 cm; range: 0.8–4.5 cm) than in mammogram detected group (1.6 cm; range 0.4–6 cm). Conclusions: These findings demonstrate the value of mammography as compared to patient detected LRs. Whether a survival advantage exists remains uncertain. Nevertheless routine physician examination in this setting is highly insensitive and its further utility must be considered when devising cost-effective strategies for surveillance of breast cancer patients. No significant financial relationships to disclose.
Task Force 2: Pediatric Training Guidelines for Noninvasive Cardiac Imaging
Authors: Stephen P. Sanders, Steven D. Colan, Timothy M. Cordes, Mary T. Donofrio, Gregory J. Ensing, Tal Geva, Thomas R. Kimball, David J. Sahn, Norman H. Silverman, Mark S. Sklansky, Paul M. Weinberg
Journal: Journal of the American College of Cardiology (2005)
Comment
Authors: Philip Rubin
Journal: JAMA (1965)

The value of selecting patients for surgery or irradiation or both by means of a screening procedure such as the cytohistopathological techniques herein described is most intriguing. If one could determine the biological aggressiveness of a neoplasm, the host resistance of the patient, and the radioresponsiveness of both tumor and normal tissue, a rational basis for therapeutic selection of patients could be made available. The main question to be answered is whether such selection can improve survival results by using various modalities of treatment. Or is the end result biologically determined and the ultimate outcome unaffected by the modality of treatment? It is gratifying to learn that survival figures as reported by Glucksmann and Way and by Graham and Graham suggest a trend in the right direction; that is, patients with poor radioresponsiveness can be salvaged by radical surgery. If this proves to be the case, application to other sites
A pilot study investigating maintenance sargramostim in patients with androgen-independent prostate cancer (AIPC) who have maximized their response to chemotherapy: preliminary results
Authors: J. D. Bitran, K. Tolzien, T. M. Lestingi, C. Nabhan
Journal: Journal of Clinical Oncology (2008)

16111 Background: There is no standard of care for AIPC patients (pts) who completed chemotherapy. Most studies report time to progression (TTP) ranging from 3 to 6 months. GM-CSF is an immune-based growth factor with reported activity in AIPC. We investigated whether implementing GM-CSF as a maintenance approach in pts who have maximized their response to chemotherapy would delay TTP and/or delay the need for further therapies. Methods: Eligible pts were those with AIPC who completed 10–12 cycles of docetaxel or mitoxantrone-based chemotherapy without evidence of disease progression biochemically or radiographically; or those who maximized their response to chemotherapy before completing 10–12 cycles. Maximum response was defined as a change in PSA by less than 10% repeated on two occasions with stable disease (SD) radiographically. Enrolled pts received GM-CSF at 250 ug/m2 subcutaneously for 14 days followed by 14-days of rest. GM-CSF was continued until disease progression. Results: To date, 10 pts have been enrolled. Median age was 79 (67–86). Median PSA at enrollment was 49.8 (0.1–566). Median number of chemotherapy cycles received prior to starting GM-CSF was 9 (5–10). Eight pts received docetaxel/prednisone and 2 pts received mitoxantrone/prednisone. GM-CSF was well-tolerated with no drug- related grade 3 and/or 4 toxicities. One pt with known cardiac disease developed atrial fibrillation that was not related to GM-CSF. One pt developed deep venous thrombosis. Eight pts are evaluable (1 patient withdrew consent and another failed to comply with mandated follow up). Median GM-CSF cycles received was 3 (2–11). With a median follow up of 6.5 months (2–12), 4 pts demonstrated SD for a median of 7 months (4–11), and 4 pts progressed within 2 months. Five pts remain alive. Two pts have not required additional therapy and 1 pt died after 11 months of unrelated causes without needing additional therapy. Three pts had PSA responses with 1 pt having > 50% PSA reduction. Conclusions: GM-CSF has activity in AIPC after stopping chemotherapy. Longer follow-up and additional accrued pts will determine whether this maintenance strategy delays TTP and the need for alternative therapy. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Bayer Bayer
Carriers in Infectious Diseases. A Manual on the Importance, Pathology, Diagnosis and Treatment of Human Carriers.
Authors: Raymond Alexander Kelser, Henry James Nichols
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 4497: Non-Selective NSAIDs Increase Incidence of Peri-Procedural Infarct and Prolong Hospital Stay after Percutaneous Coronary Interventions
Authors: Rizwan Alimohammad, Sara Westergaard, Mikhail Torosoff
Journal: Circulation (2008)

Non-steroidal anti-inflammatory drugs (NSAIDs) increase risk of CV events. We sought to evaluate hospital outcomes associated with NSAID therapy in patients undergoing percutaneous coronary interventions (PCI). Data on NSAID use in single institution treated, consecutive PCI patients (treatment period 2004 –2006, rofecoxib-treated subjects excluded) was merged with NY State Angioplasty Registry database, and studied with ANOVA, chi-square, Kaplan-Meier, and logistic regression analyses. Of 2933 ASA-treated PCI patients (29% females) only 78 (2.7%) were treated with non-selective (ns) NSAIDs and 15 (0.5%) with Celecoxib. Most commonly used ns-NSAIDs were Ibuprofen (n=47) and Ketorolac (n=16). Most common indications for NSAIDs were musculoskeletal pain (35%) or “non-cardiac” chest pain (9%). NSAID-treated patients were younger (56+/−12 in ns-NSAID, 60+/−12 in Celecoxib, and 62+/−12 years old in “no NSAID” groups; p&lt;0.001). More NSAID-treated patients had a history of myocardial infarction (p&lt;0.001) or reduced ejection fraction (p=0.008). NSAIDs treatment did not affect post-PCI in-hospital mortality (p=0.769). However, post-procedural myocardial infarction (MI) was more common in ns-NSAID-treated patients (5% in ns-NSAID, 0% in Celecoxib, and 1% in “no NSAID” groups, p=0.002), odds ratio 5.4 (95%CI of 1.9 –15.9, p=0.002). Post-procedural length of stay in survivors was also significantly longer in the ns-NSAID group (3.9+/− 3.4 days), as compared to Celecoxib (1.1+/− 0.3 days) or “no NSAID” groups (2.2 +/−3.3 days; p&lt;0.001). Ns-NSAID treatment remained predictive of prolonged hospital stay (p=0.011) after adjustment for age (p=0.033), ejection fraction (p&lt;0.001), and history of previous (p&lt;0.001) or post-procedural MI (p=0.001). We observed an increased incidence of peri-procedural MI and longer post-PCI length-of-stay in patients treated with non-selective NSAIDs, but not with Celecoxib. Poor outcomes in ns-NSAIDs treated PCI patients may be due to attenuation of aspirin’s anti-platelet effects by ns-NSAIDs. Pending results of the randomized trials, providers should limit use on non-selective NSAIDs in patients with coronary artery disease undergoing PCI.
Postoperative Interferon Alpha Treatment of Patients with Hepatocellular Carcinoma: Expression of p48 Using Tissue Microarray
Authors: Hui-Chuan Sun
Journal: Liver Cancer (2009)

Hepatocellular carcinoma (HCC) is a major health problem in China and the third most common cause of cancer death in the world (Parkin et al., 2005). Surgical resection can have a curative outcome, but > 50% of patients will have recurrence in the first 5 years after resection (Poon, 2007), and the recurrence usually results in death (Regimbeau et al., 2004). No standard postoperative adjuvant therapy has yet been established (Sun and Tang, 2003). In a previous study, we demonstrated that interferon-α (IFN-α) delays tumor growth and inhibits metastasis in a nude mouse model (Wang et al., 2000). Further studies revealed that both antiangio-genesis and antiproliferative effects are involved in the antitumor effect in the HCC model (Wang et al., 2003; Wu et al., 2004, 2005). In addition to the direct antitumor effect, the antivirus effect may also be involved in the prevention of recurrence of HCC. Some reports have indicated that long-term IFN-α reduces the incidence of HCC in patients with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (Lin et al., 2007; Y u et al., 2006).
The Monoclonal Gammopathies. Multiple Myeloma and Related Plasma-Cell Disorders.
Authors: Robert A. Kyle, Edwin D. Bayrd
Journal: Annals of Internal Medicine (1977)

pathophysiological basis of these diseases.These will prove most useful to all workers in the field.The book is elegantly illustrated and produced, and it is remarkably well indexed and provided with references, some of which are as recent as 1976 -one advantage of writing singlehanded.
AML M0.の明確なサブタイプである骨髄/NK前駆細胞急性白血病
Authors: Suzuki R, Murata M, Kami M, Ohtake S, Asou N, Kodera Y, Seto M, Hamajima N, Shimoyama M, Ohno R, Morishima Y, Nakamura S
Journal: Blood (2001)
Abstract 49: Comparison of Intraosseous Proximal Humerus and Sternal Routes for Drug Delivery during CPR
Authors: Stephen L Hoskins, Brian S Zachariah, Nick Copper, George C Kramer
Journal: Circulation (2007)

Intravenous access can be delayed during medical emergencies such as shock and cardiac arrest. The intraosseous (IO) route delivers drugs into the non-collapsible vessels within the bone marrow and...